Illumina this week said that it has appointed Jack Goldstein to its board of directors.
Goldstein was most recently president and COO of Chiron Corporation until its acquisition by Novartis in April 2006. Prior to Chiron, he spent two years as a general partner at Windamere Venture Partners, preceded by four years at Applied Imaging, where he served as president and CEO, and later as chairman. Goldstein worked for more than 10 years at Ortho Diagnostic Systems in several positions, including president. He was earlier vice president of research and development at a division of Baxter Healthcare. Goldstein holds a BA in biology from Rider University, and an MS in immunology and PhD in microbiology from St. John's University. He currently sits on the board of directors of Orasure Technologies.
Exelixis said this week that Gisela Schwab had been appointed senior vice president and chief medical officer. She will report to Jeffrey Latts, the company's executive vice president of development.
Schwab most recently served as senior vice president and chief medical officer at Abgenix, where beginning in 1994 she led worldwide product development activities, including preclinical development; pharmacokinetics and toxicology; regulatory affairs and clinical development in diverse therapeutic areas, including hematology and oncology. Previously she served as vice president of clinical development at Abgenix from 1999 to 2001. Between 1992 and 1999, she held several positions at Amgen, most recently as therapeutic area leader for the clinical development of hematology and oncology pipeline. Schwab earned an MD from the University of Heidelberg, trained at the National Cancer Institute and is board certified in internal medicine and hematology and oncology.
Luminex said this week that several management changes will be effective July 1.
James Jacobson has been named to the new position of vice president and CSO. He will also continue in his role as chairman of the scientific advisory board.
John Carrano has been named vice president of research and development. Carrano will join the scientific advisory board.
Oliver Meek has been named to the new position of vice president of quality assurance and regulatory affairs.
Cepheid this week launched its CE-marked Smart CMV in vitro diagnostic test in Europe for the SmartCycler real-time PCR platform. The test is intended for rapid detection and quantitation of CMV viral load for hospitals, university research labs, and government agencies, the company said. With automation, the SmartCycler system can deliver "highly accurate and consistent test results from prepared biological samples in approximately 30-40 minutes," Cepheid added.
SuperArray Bioscience last week launched its ArrayGrade FFPE RNA Isolation Kit for isolating RNA from formalin-fixed paraffin-embedded samples for microarray-based gene expression analysis.
The company claims the kit can help increase percent positive calls on high-density microarrays by reversing more of the cross-links introduced by the archiving process and recommended its use in cancer and pathology research.